Patents-Review.com
ClassID:

116530 ⎘

C12Y302/01036 - CPC Classification

Classification description:

Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2); Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1) Hyaluronoglucuronidase (3.2.1.36)

Recent Application in this class:
#1
20240009282
2024-01-11

PERI-ORBITAL FULLNESS ASSESSMENT SCALE AND METHODS OF USE THEREOF

 #2
20230024365
2023-01-26

Strain of Enterobacter for degrading hyaluronic acid and application thereof

 #3
20230012731
2023-01-19

HYALURONIDASE COMPOSITIONS AND METHODS OF USING SAME TO TREAT PERI-ORBITAL HOLLOWNESS AND TEAR THROUGH DEFORMITIES

 #4
20220168403
2022-06-02

SUBCUTANEOUS TELOMERASE INHIBITOR COMPOSITIONS AND METHODS FOR USING SAME

 #5
20210388070
2021-12-16

CO-ADMINISTRATION OF A HYALURONIDASE AND ANTI-C5 ANTIBODY FOR TREATMENT OF COMPLEMENT-ASSOCIATED CONDITIONS

 #6
20210198620
2021-07-01

ENTEROBACTER AND ITS APPLICATION

 #7
20200354689
2020-11-12

Methods and devices related to controlled delivery of phages as a theranostic tool

 #8
20190219579
2019-07-18

METHODS AND SYSTEMS FOR SCORING EXTRACELLULAR MATRIX BIOMARKERS IN TUMOR SAMPLES

 #9
20150031085
2015-01-29

Leech hyaluronidase and its application

 #10
20140322192
2014-10-30

Proteoglycan degrading mutants for treatment of CNS

 #11
20120196348
2012-08-02

Large-scale production of soluble hyaluronidase

 #12
20110250631
2011-10-13

PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS

 #13
20110053247
2011-03-03

Large-scale production of soluble hyaluronidase

 #14
20090041728
2009-02-12

Proteoglycan degrading mutants for the treatment of CNS

 #15
20090028829
2009-01-29

Fusion proteins for the treatment of CNS

 #16
20070134228
2007-06-14

Human plasma hyaluronidase

 #17
20060233782
2006-10-19

Proteoglycan degrading mutants for the treatment of CNS